NanoViricides Inc. (NNVC)

[KMBJN]

Agree, but also speculate that a topical 'cide (HerpesCide gel) would require much less material for tox testing. It's a much smaller volume on a small skin/mucosal surface lesion than the entire bloodstream of animals (IV injection).

It's a tough decision with limited production capacity and capital, how to choose the best viral target to pursue first/next. I think Seymour is going for "bang for the buck" in terms of how much you can get for each gram of 'cide. He's also considering speed of testing - acute viral illnesses (like flu) versus chronic (like HIV), but I think they have dropped the ball on production capacity - taking much longer than anyone ever expected. If a small quantity of topical product could get through testing and bring in revenue quicker, it might be worth pursuing, even if other drugs would prove more lucrative later on.